APA (7th ed.) Citation

NC, Y., C, B., D, T., WC, W., KR, W., A, W., . . . JM, L. (2019). A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. Molecular pharmaceutics, 16(9), 3926. https://doi.org/10.1021/acs.molpharmaceut.9b00529

Chicago Style (17th ed.) Citation

NC, Yoder, et al. "A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation." Molecular Pharmaceutics 16, no. 9 (2019): 3926. https://doi.org/10.1021/acs.molpharmaceut.9b00529.

MLA (9th ed.) Citation

NC, Yoder, et al. "A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation." Molecular Pharmaceutics, vol. 16, no. 9, 2019, p. 3926, https://doi.org/10.1021/acs.molpharmaceut.9b00529.